---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039057"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:27:32.156044+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CRISPR Q2 2023 net loss $77.7M; FDA accepts exa-cel BLAs with PDUFA Dec 8 for SCD

## Summary
- FDA accepted BLAs for exa-cel: Priority Review for SCD (PDUFA Dec 8, 2023), Standard Review for TDT (Mar 30, 2024).
- Net loss narrowed to $77.7M from $185.8M YoY; collaboration revenue $70M from Vertex milestone.
- Cash and accounts receivable $1,843M; R&D spend $101.6M, down from $123.2M Q2 2022.
- Vertex licensing: $100M upfront received, $70M milestone receivable, up to $230M additional milestones.
- Pipeline: CTX110/130/112/131 trials ongoing; in vivo CTX310 (ANGPTL3) enters clinic in 2023.

## SEC filing metadata
- accession: 0000950170-23-039057
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017023039057/0000950170-23-039057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017023039057/crsp-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039057
- JSON: https://secwatch.observer/filing/0000950170-23-039057.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039057.txt

## Key facts
- Earnings Releases
  CRISPR Therapeutics AG reported financial results for quarter ended June 30, 2023.
  - Period: quarter ended June 30, 2023
  - Result: reported results
  source text: On August 7, 2023, CRISPR Therapeutics AG announced its financial results for the quarter ended June 30, 2023 and other business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017023039057/0000950170-23-039057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.